Home
HelpTest ID KRASD Cell-Free DNA KRAS 12, 13, 61,146, Blood
Ordering Guidance
This test is not a prenatal screening test. To evaluate for the presence of common fetal chromosome abnormalities using cell-free DNA, order NIPS / Cell-Free DNA Prenatal Screen.
Shipping Instructions
1. Samples should be transported at ambient temperature or refrigerated (4° C).
2. Samples are viable for 7 days in the Streck Black/Tan Top Tube Kit (T715).
Specimen Required
Supplies: Streck Black/Tan Top Tube Kit (T715)
Container/Tube: Streck Cell-Free DNA blood collection kit (T715)
Specimen Volume: Two 10-mL Streck Cell-Free DNA blood collection tubes
Additional Information: Only blood collected in Streck Cell-Free DNA BCT tubes will be accepted for analysis. Whole blood will be processed to produce platelet-poor plasma before cfDNA isolation.
Useful For
As an alternative to invasive tissue biopsies for the determination of KRAS 12, 13, 61,146 (G12A, G12C, G12D, G12R, G12S, G12V, G13D, Q61K, Q61L, Q61R, Q61H, and A146T) mutation status
Selection of patients with colorectal cancer who are most likely to benefit from epidermal growth factor receptor (EGFR)-targeted therapies
Genetics Test Information
This test evaluates cell-free DNA (cfDNA) in the peripheral blood for the presence of KRAS mutations at codons 12, 13, 61, and 146 (G12A, G12C, G12D, G12R, G12S, G12V, G13D, Q61K, Q61L, Q61R, Q61H, and A146T) in patients with colorectal cancer and can be used to assess eligibility for targeted therapies.
This test is not validated for serial monitoring of patients with cancer. This test is also not intended as a screening test to identify cancer.
Highlights
This test provides rapid detection of KRAS mutations in colorectal cancer patients as an alternative for KRAS analysis of tissue.
Current data suggests that the efficacy of epidermal growth factor receptor (EGFR)-targeted therapy in colorectal cancer patients is limited to patients whose tumors do not harbor mutations in the KRAS gene.
Method Name
Digital Droplet Polymerase Chain Reaction (PCR)
Reporting Name
cfDNA KRAS 12, 13, 61, 146 BloodSpecimen Type
Whole bloodSpecimen Minimum Volume
One 10 mL Streck tube
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Whole blood | Ambient (preferred) | 7 days | Streck Black/Tan top |
| Refrigerated | 7 days | Streck Black/Tan top |
Day(s) Performed
Monday through Friday
Report Available
5 to 10 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
81275
81276
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| KRASD | cfDNA KRAS 12, 13, 61, 146 Blood | In Process |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 113123 | Result Summary | 50397-9 |
| 113508 | Result | 75974-6 |
| 113125 | Interpretation | 69047-9 |
| 113126 | Additional Information | 48767-8 |
| 113127 | Specimen | 31208-2 |
| 113128 | Source | 31208-2 |
| 113129 | Released By | 18771-6 |
NY State Approved
YesForms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.